Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, Brijesh Gautama, Aikaterini Panapoulou, Sumantha Gabriel, Ram Malladi, Jessica Pealing, Denise Bonney, Emma Nicholson, Caroline Besley, Sara Ghorashian, Elizabeth Davies, Jackie Chappell, Anne Black, Tobias Menne, Maeve O'Reilly, Robin Sanderson, Sridhar Chaganti

Blood (2023) 142 (Supplement 1): 495.

https://doi.org/10.1182/blood-2023-178834

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Blocking T Cell Co-Stimulation Via CD70 As a Target for Gvhd in Allogeneic Stem Cell Transplantation (SCT)

Kriti Verma, Jianmin Zuo, Christine Stephens, Francesca A Kinsella, Ram Malladi, Paul Moss

Blood (2022) 140 (Supplement 1): 12665.

https://doi.org/10.1182/blood-2022-169601

Published: 2022

Journal Articles

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 7509–7511.

https://doi.org/10.1182/blood-2022-169459

Published: 2022

Journal Articles

Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes

Ruta Maniusyte, Angharad Pryce, Rachel Pearce, John A Snowden, Ram Malladi, Victoria Potter, Julia Lee, Marie Wilson, Antonio Pagliuca, Eduardo Olavarria, Renuka Palanicawandar, Chloe Anthias, Rachel Pawson, Robert David Danby

Blood (2022) 140 (Supplement 1): 7552–7554.

https://doi.org/10.1182/blood-2022-163039

Published: 2022

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Blood (2021) 138 (Supplement 1): 430.

https://doi.org/10.1182/blood-2021-147598

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 324.

https://doi.org/10.1182/blood-2019-128795

Published: 2019

Journal Articles

Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 3338.

https://doi.org/10.1182/blood-2019-123827

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT

Joshua Fein, Myriam Labopin, MD, Roni Shouval, MD PhD, Gerard Socie, MD PhD, Jürgen Finke, MD, Jan J Cornelissen, MD PhD, Ram Malladi, Maija Itälä-Remes, MD PhD, Patrice Chevallier, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Donald Bunjes, MD, Mahmoud Aljurf, MD, Marie Thérèse Rubio, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 203.

https://doi.org/10.1182/blood-2018-99-113296

Published: 2018

Journal Articles

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Blood (2018) 132 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2018-99-115167

Published: 2018

Journal Articles

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Charles Craddock, Wendy Ingram, Daniel Slade, Andrea Hodgkinson, BSc(Hons),PhD, Francis J. Mussai, MA, MD DPhil, Carmela De Santo, Jamie Cavenagh, Michael Dennis, MDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD, Shamyla Siddique, BSc.(Hons.), MPhil, Yap Christina, MSci, PhD CStat

Blood (2017) 130 (Supplement 1): 276.

https://doi.org/10.1182/blood.V130.Suppl_1.276.276

Published: 2017

Journal Articles

NK Cells Produce High Levels of IL-10 Early after Allogeneic Stem Cell Transplantation and Suppress Development of Acute GVHD

Paul Moss, MBBS, PhD FRCP, Ram Malladi, MRCP, FRCPath, PhD, Tracey Chan, PhD, Jianmin Zuo, PhD

Blood (2017) 130 (Supplement 1): 5489.

https://doi.org/10.1182/blood.V130.Suppl_1.5489.5489

Published: 2017

Journal Articles

An ABVD-Based Approach Confers Superior Outcomes for Adolescent and Young Adult Patients Compared to Other Adults with Advanced Classical Hodgkin Lymphoma

David M Burns, BSc,MBBS,MRCP, Andrew Bacon, BSc, MSc, Timothy HT Wong, MBBChir, Guy Pratt, MD FRCP, FRCPath, Fiona J Clark, MBBChir, FRCP, FRCPath, Premini Mahendra, MD FRCP, FRCPath, Sridhar Chaganti, MDPhDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD

Blood (2017) 130 (Supplement 1): 4083.

https://doi.org/10.1182/blood.V130.Suppl_1.4083.4083

Published: 2017

NARROW

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blocking T Cell Co-Stimulation Via CD70 As a Target for Gvhd in Allogeneic Stem Cell Transplantation (SCT)

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

NK Cells Produce High Levels of IL-10 Early after Allogeneic Stem Cell Transplantation and Suppress Development of Acute GVHD

An ABVD-Based Approach Confers Superior Outcomes for Adolescent and Young Adult Patients Compared to Other Adults with Advanced Classical Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only